The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
983
September 13, 1996
View Complete Issue         Table of Contents 2019 
Fluticasone Propionate for Chronic Asthma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Fluticasone Propionate for Chronic Asthma
September 13, 1996 (Issue: 983)
An inhalation aerosol formulation of the corticosteroid fluticasone propionate (Flovent -Glaxo Wellcome) has been approved by the US Food and Drug Administration for maintenance treatment of asthma.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Fluticasone Propionate for Chronic Asthma
Article code: 983a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.